San Diego, CA – April 3, 2026 – SeekIn Inc. (“SeekIn”), a leader in blood-based cancer early detection, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,592,320 B2, titled “Methods of Detecting Cancer,” covering key aspects of the company’s OncoSeek® multi-cancer early detection (MCED) test. The patent was filed as U.S. Application No. 18/620,367 on March 28, 2024 and issued on March 31, 2026.
U.S. Patent 12,592,320 B2 protects methods of cancer early detection using a panel of selected protein tumor markers combined with artificial intelligence-based algorithms to distinguish cancer from non-cancer individuals. The patented technology uses several serum protein tumor markers together with age and sex to calculate a probability of cancer (POC) index, enabling effective and affordable multi-cancer early detection with high specificity. In large-scale, multicenter studies involving more than 15,000 participants across multiple cohorts, the OncoSeek® model demonstrated robust performance, with area under the curve (AUC) value up to 0.88, and 58% sensitivity at 92% specificity.
Beyond detecting the presence of cancer signals, the patented methods also include AI models that help predict the likely tissue of origin (TOO), leveraging tissue-specific patterns of protein tumor markers. In the study, the top two predicted organ systems were correct in 71% patients, providing actionable guidance to clinicians on follow-up diagnostic workups.
“This U.S. patent grant is an important milestone for SeekIn and validates our vision of making affordable, accessible multi-cancer early detection a reality worldwide,” said Dr. Mao Mao, Founder & CEO of SeekIn Inc. “By combining widely available protein tumor markers with advanced AI, OncoSeek is designed for real-world implementation, especially in health systems and regions where complex genomic testing is not feasible.”
The patented OncoSeek® approach uses existing clinical analyzers and standard serum or plasma samples, enabling integration into routine health checkups and population-level screening programs. By optimizing the use of conventional tumor markers and overcoming the high false-positive rates seen when markers are interpreted with traditional single-threshold methods, OncoSeek®’s AI model maintains high specificity while significantly improving sensitivity, particularly for cancers such as pancreatic, ovarian, liver, and lung cancer.
“With this patent, SeekIn has secured a strong intellectual property foundation in the United States for our protein-based MCED strategy, complementing our broader global patent portfolio,” said Ms. Shujia Hao, Co-founder & CFO. “We look forward to advancing clinical collaborations, regulatory submissions, and commercial partnerships to bring OncoSeek® to more patients.”
About OncoSeek®
OncoSeek® is SeekIn’s proprietary multi-cancer early detection test that uses a panel of seven serum protein tumor markers and patient clinical information, analyzed by artificial intelligence-based models, to detect cancer signals and suggest likely tissue of origin. Designed to run on widely deployed analytical platforms such as Roche cobas analyzers and similar systems, OncoSeek® aims to deliver accurate, cost-effective cancer screening suitable for large-scale implementation, including in resource-constrained settings.